Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Sep;69(5):775-788.
doi: 10.1007/s10384-025-01210-6. Epub 2025 May 16.

Intravenous immunoglobulin for the acute treatment of refractory optic neuritis in Japan

Yohei Takahashi  1   2 , Takeshi Kezuka  3 , Keigo Shikishima  4 , Akiko Yamagami  5 , Hideki Chuman  6 , Makoto Nakamura  7 , Satoshi Ueki  8 , Akiko Kimura  9 , Masato Hashimoto  10 , Sonoko Tatsui  11 , Nobuyuki Shoji  11 , Hitoshi Ishikawa  12 ; Collaborative Research Group: Investigators
Collaborators, Affiliations
Multicenter Study

Intravenous immunoglobulin for the acute treatment of refractory optic neuritis in Japan

Yohei Takahashi et al. Jpn J Ophthalmol. 2025 Sep.

Abstract

Purpose: To investigate the usage status and evaluate the efficacy of intravenous immunoglobulin (IVIG) for the acute treatment of optic neuritis (ON) in Japan.

Study design: Multicenter retrospective case series.

Methods: The study subjects were patients with steroid-resistant acute ON in whom IVIG had been initiated between January 2020 and August 2022 at 30 facilities in Japan. The clinical characteristics, visual acuity, and adverse events following IVIG were compared among anti-aquaporin 4 antibody positive ON (AQP4-ON), anti-myelin oligodendrocyte glycoprotein antibody positive ON (MOG-ON), and idiopathic ON (ION).

Results: The study included sixty-five patients (76 eyes); the main clinical department administering IVIG was ophthalmology (50 cases, 77.0 %). 43 cases had their first ON attack and 22 cases had recurrent ON. Plasmapheresis (PP) was combined in 21 cases. The efficacy endpoint, changes in logarithm of the minimum angle of resolution (logMAR) after IVIG compared with preIVIG, showed statistically significant improvement in the AQP4-ON group at one week, 4 weeks, and 12 weeks after IVIG (p=0.015, p<0.001, p<0.001, respectively). In the MOG-ON group, excluding cases with combined PP, logMAR post IVIG did not improve significantly compared with preIVIG. Among the ION group, compared with preIVIG, logMAR at 4weeks and 12 weeks post IVIG were statistically significant improved (p=0.019, p=0.023, respectively). Adverse events occurred in 7 patients with IVIG. 4 of the 7 patients continued the IVIG treatment, and 3 patients discontinued it within 5 days.

Conclusion: This study demonstrates that IVIG may be an effective new option for acute treatment of steroid-resistant ON as an add-on to conventional therapy.

Keywords: Intravenous immunoglobulin; Optic neuritis; Plasmapheresis; Steroid-resistant.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflicts of interest: Y. Takahashi, None; T. Kezuka, Nonfinancial support (UCB, Chugai, Cosmic Corp, Mitsubishi Tanabe, Santen, Senju, Teijin, Nitto Medic, ALEXION, Takeda, Novartis, AbbVie); Consulting fees (UCB, Chugai, ALEXION), Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Chugai, Teijin, AbbVie, Mitsubishi Tanabe, Cosmic Corp, Santen, Senju, Teijin, Takeda, Novartis, Nitto Medic, ALEXION); K. Shikishima, None; A. Yamagami, None; H. Chuman, None; M. Nakamura, None; S. Ueki, None; A. Kimura, None; M. Hashimoto, None; S. Tatsui, None; N. Shoji, None; H. Ishikawa, Nonfinancial support (Santen, Chugai, ALEXION), Consulting fees (Chugai, Santen, ALEXION).

Figures

Fig. 1
Fig. 1
Changes in logMAR (mean ± standard error) before intravenous immunoglobulin among three optic neuritis groups.**: p<0.01, logMAR logarithm of the minimum angle of resolution, SP steroid pulse, IVIG intravenous immunoglobulin, AQP4-ON anti-aquaporin 4 antibody positive optic neuritis, MOG-ON anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis, ION idiopathic optic neuritis, SE standard error.
Fig. 2
Fig. 2
Changes in logMAR (mean ± standard error) after intravenous immunoglobulin among three optic neuritis groups. *: p<0.05 **: p<0.01 ***: p<0.001. logMAR logarithm of the minimum angle of resolution, IVIG intravenous immunoglobulin, AQP4-ON anti-aquaporin 4 antibody positive optic neuritis, MOG-ON anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis, ION idiopathic optic neuritis, SE standard error
Fig. 3
Fig. 3
Changes in logMAR (mean ± standard error) before and after intravenous immunoglobulin without plasmapheresis among three optic neuritis groups. logMAR logarithm of the minimum angle of resolution, SP steroid pulse, IVIG intravenous immunoglobulin, AQP4-ON anti-aquaporin 4 antibody positive optic neuritis, MOG-ON anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis, ION idiopathic optic neuritis, PP plasmapheresis, SE standard error
See this image and copyright information in PMC

References

    1. Beck RW, Cleary PA, Anderson MM Jr, Keltner JL, Shults WT, Kaufman DI, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992. 10.1056/NEJM199202273260901. - PubMed
    1. Wakakura M, Mashimo K, Oono S, Matsui Y, Tabuchi A, Kani K, et al. Multicenter clinical trial for evaluating methylprednisolone pulse treatment of idiopathic optic neuritis in Japan. Optic neuritis treatment trial multicenter cooperative research group (ONMRG). Jpn J Ophthalmol. 1999. 10.1016/S0021-5155(98)00071-9. - PubMed
    1. Petzold A, Fraser CL, Abegg M, Alroughani R, Alshowaeir D, Alvarenga R, et al. Diagnosis and classification of optic neuritis. Lancet Neurol. 2022;21:1120–34. - PubMed
    1. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. (International panel for NMO diagnosis) international consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015. 10.1212/WNL.0000000000001729. - PMC - PubMed
    1. Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria. Lancet Neurol. 2023;22:268–82. - PubMed

Publication types

MeSH terms

LinkOut - more resources